<u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: BELL Michael Gregory Group Art Unit: 1624

Serial No.: 10/598,686 Examiner: COLEMAN, BRENDA LIBBY

Application Date: March 17, 2005 Conf No.: 8979

US Nat'l Entry Date (if applicable): September 8, 2006

For: COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

Docket No.: X17098

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

As a means of complying with the duty of disclosure under 37 CFR §1.56, Applicants submit the attached Form PTO-1449 (modified) and provide a copy of the listed foreign patent document, which is a machine translation of an previously submitted Japanese publication. The US Patent Publications have not been submitted. However, the undersigned attorney would be happy to provide to the examiner with copies upon request by the Examiner. The filing of this Statement is not an admission that that cited information is or is not material to the patentability of the claimed invention.

Since this Statement is being filed prior to receipt of the first substantive office action in accordance with 37 C.F.R. §1.97(b), Applicants submit that no fee is required. However if this is in error, please charge any fees or credit any over payment to deposit account no. 05-0840.

Applicants request consideration of this information.

Respectfully submitted, /James B. Myers/ James B. Myers Attorney for Applicants Registration No. 42,021 Phone: 317-276-0755

Eli Lilly and Company Patent Division P.O. Box 6288

Indianapolis, Indiana 46206-6288